Physician profile
Shaena Freeman
NPI 1023490943
$879.84
in general payments reported to CMS, 2019-2025
16 companies · $30.17 in 2025
The $30.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $81.65 · 2021: $19.06 · 2022: $662 · 2023: $69.80 · 2024: $16.90 · 2025: $30.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $181.07 | 2022-2023 | Veozah |
| Amgen INC. | $120.78 | 2020-2022 | |
| Lilly USA, LLC | $104.01 | 2022-2024 | Mounjaro |
| Pfizer INC. | $89.94 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $67.78 | 2022 | |
| Glaxosmithkline, LLC. | $52.62 | 2022-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $46.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.22 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $34.39 | 2022 | |
| Ibsa Pharma INC. | $26.29 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.20 | 2022 | |
| Janssen Biotech, INC. | $21.44 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.06 | 2021 | |
| Abbvie INC. | $18.45 | 2022 | |
| Merck Sharp & Dohme LLC | $16.32 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.17 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaena Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.